Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$14.65 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
3.66 billion
Earnings per share
-0.012
Dividend per share
N/A
Year To Date Return
-88.24%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
⏸️ Investing
Why these 4 ASX shares have posted strong gains today
⏸️ Investing
Impedimed Limited share price climbs higher on FDA clearance
⏸️ Investing
Why these 4 ASX shares have climbed higher today
⏸️ Investing
The ImpediMed Limited share price has jumped: Here's why
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
Why these 4 ASX shares have rocketed higher today
⏸️ Investing
Why these 4 ASX shares have started the week deep in the red
⏸️ Investing
Why these 4 ASX shares surged higher today
⏸️ Investing
Why these 4 ASX shares have bolted higher today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
4 small-cap shares I think could be set to soar in 2017
⏸️ Investing
3 game-changing companies to buy today
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Oct 2026 | $0.00 | $0.00 | 0.00% | 2,700,576 | $0.00 | $0.00 | $0.00 |
| 21 Oct 2026 | $0.00 | $0.00 | 0.00% | 2,499,964 | $0.01 | $0.01 | $0.00 |
| 20 Oct 2026 | $0.00 | $0.00 | 0.00% | 73,686,544 | $0.01 | $0.01 | $0.00 |
| 19 Oct 2026 | $0.01 | $0.00 | 0.00% | 1,989,654 | $0.01 | $0.01 | $0.01 |
| 16 Oct 2026 | $0.01 | $0.00 | 0.00% | 1,738,574 | $0.01 | $0.01 | $0.01 |
| 15 Oct 2026 | $0.01 | $0.00 | 0.00% | 7,252,838 | $0.01 | $0.01 | $0.01 |
| 14 Oct 2026 | $0.01 | $0.00 | 0.00% | 2,185,525 | $0.01 | $0.01 | $0.01 |
| 13 Oct 2026 | $0.01 | $0.00 | 0.00% | 3,223,784 | $0.01 | $0.01 | $0.01 |
| 09 Oct 2026 | $0.01 | $0.00 | 0.00% | 397,004 | $0.01 | $0.01 | $0.01 |
| 08 Oct 2026 | $0.01 | $0.00 | 0.00% | 8,302,634 | $0.01 | $0.01 | $0.01 |
| 07 Oct 2026 | $0.01 | $0.00 | 0.00% | 7,143,844 | $0.01 | $0.01 | $0.01 |
| 06 Oct 2026 | $0.01 | $0.00 | 0.00% | 19,999,782 | $0.01 | $0.01 | $0.01 |
| 05 Oct 2026 | $0.01 | $0.00 | 0.00% | 966,006 | $0.01 | $0.01 | $0.01 |
| 02 Oct 2026 | $0.01 | $0.00 | 0.00% | 10,616,569 | $0.01 | $0.01 | $0.01 |
| 01 Oct 2026 | $0.00 | $0.00 | 0.00% | 6,715,299 | $0.01 | $0.01 | $0.00 |
| 30 Sep 2026 | $0.01 | $0.00 | 0.00% | 7,392,677 | $0.01 | $0.01 | $0.01 |
| 29 Sep 2026 | $0.00 | $0.00 | 0.00% | 6,492,453 | $0.01 | $0.01 | $0.00 |
| 28 Sep 2026 | $0.01 | $0.00 | 0.00% | 53,359,384 | $0.01 | $0.01 | $0.00 |
| 25 Sep 2026 | $0.01 | $0.00 | 0.00% | 9,745,641 | $0.01 | $0.01 | $0.00 |
| 24 Sep 2026 | $0.01 | $0.00 | 0.00% | 370,925 | $0.01 | $0.01 | $0.00 |
| 23 Sep 2026 | $0.01 | $0.00 | 0.00% | 2,025,000 | $0.01 | $0.01 | $0.01 |
| 22 Sep 2026 | $0.01 | $0.00 | 0.00% | 3,593,345 | $0.01 | $0.01 | $0.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Sep 2026 | Erik Anderson | Buy | 42,301,480 | $211,507 |
On-market trade.
|
| 03 Jul 2026 | Janelle Delaney | Issued | 595,000 | $3,570 |
Director remuneration.
|
| 03 Jul 2026 | Erik Anderson | Issued | 37,088 | $222 |
Director remuneration.
|
| 03 Jul 2026 | Andrew Grant | Issued | 595,000 | $3,570 |
Director remuneration.
|
| 03 Jul 2026 | Christine Emmanuel-Donnelly | Issued | 866,250 | $5,197 |
Director remuneration.
|
| 03 Jul 2026 | Fiona Bones | Issued | 595,000 | $3,570 |
Director remuneration.
|
| 16 Jun 2026 | Christine Emmanuel-Donnelly | Issued | 10,000,000 | $100,000 |
Placement.
|
| 16 Jun 2026 | Janelle Delaney | Issued | 10,000,000 | $100,000 |
Placement.
|
| 16 Jun 2026 | Janelle Delaney | Issued | 20,000,000 | $100,000 |
Issue of options.
|
| 16 Jun 2026 | Christine Emmanuel-Donnelly | Issued | 20,000,000 | $100,000 |
Issue of options.
|
| 16 Jun 2026 | Fiona Bones | Issued | 40,000,000 | $200,000 |
Issue of options.
|
| 16 Jun 2026 | Andrew Grant | Issued | 10,000,000 | $50,000 |
Issue of options.
|
| 16 Jun 2026 | Erik Anderson | Issued | 15,000,000 | $150,000 |
Placement.
|
| 16 Jun 2026 | Erik Anderson | Issued | 30,000,000 | $150,000 |
Issue of options.
|
| 16 Jun 2026 | Andrew Grant | Issued | 5,000,000 | $50,000 |
Placement.
|
| 16 Jun 2026 | Fiona Bones | Issued | 20,000,000 | $200,000 |
Placement.
|
| 02 Jun 2026 | Janelle Delaney | Issued | 221,739 | $3,569 |
Director remuneration.
|
| 02 Jun 2026 | Andrew Grant | Issued | 221,739 | $3,569 |
Director remuneration.
|
| 02 Jun 2026 | Christine Emmanuel-Donnelly | Issued | 322,826 | $5,197 |
Director remuneration.
|
| 02 Jun 2026 | Erik Anderson | Issued | 69,690 | $1,122 |
Director remuneration.
|
| 02 Jun 2026 | Fiona Bones | Issued | 221,739 | $3,569 |
Director remuneration.
|
| 05 Feb 2026 | Christine Emmanuel-Donnelly | Buy | 1,500,000 | $29,359 |
On-market trade.
|
| 14 Jan 2026 | Janelle Delaney | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Christine Emmanuel-Donnelly | Issued | 146,408 | $5,197 |
Director remuneration.
|
| 14 Jan 2026 | Andrew Grant | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Fiona Bones | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Andrew Grant | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Janelle Delaney | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Christine Emmanuel-Donnelly | Issued | 143,182 | $5,197 |
Director remuneration.
|
| 03 Nov 2025 | Fiona Bones | Issued | 98,347 | $3,569 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
Mr Grant has 20+ years of experience working with healthcare customers and healthcare markets in the United States and internationally. Has experience in strategic planning and delivery within healthcare organizations. He is a member of the People and Culture Committee and the Risk Management Committee.
|
| Mr McGregor Grant | Executive DirectorChief Financial Officer | Feb 2024 |
Mr Grant has experience in financial management, operations, governance, board administration and investor relations within healthcare and medical technology businesses.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Ms Donnelly has 30 years in IP expertise through commercialization and strategic in-house intellectual property roles and has 5+ years in Board/healthcare governance experience. She is Chair of the People and Culture Committee and member of the Risk Management Committee.
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
Ms Delaney has 30+ years of experience in project management and delivery across Asia Pacific operations, including responsibility for project quality and execution. She is a member of the People and Culture Committee and Risk Management Committee.
|
| Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones has 30+ years of global experience in finance, corporate governance and systems transformation, including international finance and governance responsibilities. She is Chair of the Risk Management Committee.
|
| Mr Erik Anderson | Non-Executive Director | Feb 2026 |
Mr Anderson has 20+ years of experience in medical technology, including commercial leadership roles in breast health, skeletal health, medical aesthetics and healthcare services.
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| Leanne Ralph | Company Secretary |
-
|
|
| Blake Ahitow | Other Corporate Officer |
-
|
|
| Erik Johnson | Other Corporate Officer |
-
|
|
| Gina Kimball | Other Corporate Officer |
-
|
|
| Julie Kuhlken | Other Corporate Officer |
-
|
|
| Ashley Munoz | Other Executive Officer |
-
|
|
| Richelle Gaw | Other Executive Officer |
-
|
|
| Scott Savage | Other Executive Officer |
-
|
|
| Chelsey Jaworski | Vice President Divisional |
-
|
|
| Scott Long | Vice President Divisional |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 412,760,595 | 11.27% |
| Citicorp Nominees Pty Limited | 319,831,151 | 8.73% |
| J P Morgan Nominees Australia Pty Limited | 98,365,316 | 2.69% |
| Fb Corp Limited As Trustee For 6 Oceans High Conviction Fund | 69,255,595 | 1.89% |
| HSBC Custody Nominees (Australia) Limited i | 62,699,915 | 1.71% |
| Mr David Matthew Fite | 61,878,094 | 1.69% |
| Mr Rodney John Charles | 57,172,443 | 1.56% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited | 56,911,582 | 1.55% |
| BNP Paribas Noms Pty Ltd | 50,756,314 | 1.39% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 50,000,000 | 1.37% |
| Moore Family Nominee Pty Ltd | 46,672,211 | 1.27% |
| BNP Paribas Nominees Pty Ltd | 43,541,754 | 1.19% |
| HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED A/C 2 | 41,895,237 | 1.14% |
| Henderson International Pty Limited | 38,011,768 | 1.04% |
| Sunlora Pty Ltd | 35,000,000 | 0.96% |
| Mr Stephen Edward Mahnken | 34,571,428 | 0.94% |
| 6 Oceans Spv1 | 34,525,100 | 0.94% |
| Henderson International Pty Limited i | 32,500,000 | 0.89% |
| Hawksburn Capital Pte Ltd | 31,349,313 | 0.86% |
| Mr Travis Fountain | 30,260,030 | 0.83% |
